Analysis

Organoids Touted as Future of Brain Disorder R&D as AxoSim Scoops Up Tech from Vyant Subsidiary

As Vyant Bio continues its wind-down, the neuroscience research assets of its subsidiary StemoniX have officially been picked up by AxoSim, a New Orleans-based drug discovery biotech.

Jenn Perkins is a seasoned commercial executive known for accelerating revenue, breaking into new markets, and fortifying brand presence within the life sciences industry.

Published
October 24, 2023
CNS
PNS
OI
Loading the Elevenlabs Text to Speech AudioNative Player...

Related Stories

In the News
7/17/2023
AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets
AxoSim has entered a definitive agreement to acquire Vyant Bio's StemoniX microBrain™ platform, uniting top-tier organoid technologies to accelerate neurological drug discovery.
In the News
2/28/2024
AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors
Serial Entrepreneurs Dale Pfost and David Weiner Bring Broad Expertise as AxoSim Expands Its Leadership in Human Organoid Technologies Designed to Make Neurological R&D Faster, More Efficient and More Successful.
In the News
6/9/2025
AxoSim Appoints Stuart Gibb as VP of Sales and Marketing to Drive Revenue Growth
AxoSim has appointed Stuart Gibb as VP of Sales and Marketing. With over 20 years of experience, Stuart will help accelerate AxoSim's commercial growth in drug discovery and development.
Join our mailing list.
Thank you! Your submission has been received.
Something went wrong while submitting the form.
© 2025 28bio. All rights reserved.
Privacy Policy
Terms of Use
FCOI Polcy